This clinical trial is focused on studying Binge Eating Disorder, a condition where individuals frequently consume large amounts of food and feel a lack of control over their eating habits. The study will explore the effectiveness of a treatment that combines food exposure therapy with a medication called Hydrocortisone. Hydrocortisone is a type of glucocorticoid, which is a hormone that can influence stress responses in the body. The trial will compare the effects of this combination treatment to a placebo, which is a substance with no active medication, to see if it helps reduce cravings for food in people with Binge Eating Disorder.

The purpose of the study is to determine if the combination of food exposure therapy and hydrocortisone is more effective than food exposure therapy alone in reducing food cravings. Participants will undergo sessions where they are exposed to real food while taking either hydrocortisone or a placebo. The study will monitor changes in food cravings, feelings of losing control over eating, and emotional responses to food over a period of time. The goal is to see if the treatment can help decrease the desire to binge eat and improve control over eating habits.

Participants will be involved in the study for a period that includes treatment sessions and follow-up assessments. The study will track the decrease in food cravings and other related behaviors both shortly after treatment and up to one month later. This research aims to provide insights into new ways to help individuals manage Binge Eating Disorder more effectively.